Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862743 | 0.88 | EGFR (0.79) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL15090523 | 0.88 | EGFR (1.00) | EGFRKDREPHB4ERBB2ERBB3 | |
| SCHEMBL255527 | 0.86 | EGFR (0.72) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL15105017 | 0.85 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL15090516 | 0.85 | EGFR (0.86) | EGFRERBB2 | |
| SCHEMBL15090527 | 0.84 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL15090569 | 0.84 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL15090676 | 0.83 | EGFR (0.83) | EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL15104756 | 0.83 | EGFR (0.83) | EGFRERBB2 | |
| Hydrochloric Acid SCHEMBL15090765 | 0.83 | EGFR (0.83) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689359-B2 | Crystals of quinazoline derivative and preparation method therefor | Xuanzhu Pharma Co., Ltd. (CN) | 2020-06-23 | — | — | US | disclosed |
| US-20190002434-A1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | Xuanzhu Pharma Co., Ltd. (CN) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002434-A1 | CRYSTALS OF QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR | WEE2, WEE1, UGT1A7 | EGFR 4228/4885EPHA2 4715/4885KDR 3266/4885 |
| US-10689359-B2 | Crystals of quinazoline derivative and preparation method therefor | WEE2, WEE1, UGT1A7 | EGFR 4184/4885EPHA2 4660/4885KDR 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.